Introduction {#Sec1}
============

Stroke is the second leading cause of death in developed countries \[[@CR1]\] and can lead to life-altering consequences \[[@CR2]\]. Guidelines recommend the use of medication for secondary prevention of stroke \[[@CR3]--[@CR5]\]. These medications target stroke risk factors such as high blood pressure and high serum cholesterol values. The medications prescribed for stroke risk factor control have shown good efficacy in the literature and reductions in the rate of stroke recurrence per annum \[[@CR6], [@CR7]\], with cumulative reductions in relative risk by as much as 75% \[[@CR8]\]. Nonetheless, adherence rates to stroke prevention medications remain suboptimal \[e.g. [@CR9], [@CR10]\].

For the purpose of this review, medication adherence is defined as "the extent to which the patient\'s action matches the agreed recommendations" \[[@CR10]\]. Among individuals with long-term conditions, 33--50% of patients were non-adherent to long-term medications \[[@CR10]\]. Among stroke survivors, a recent systematic review reported a pooled prevalent non-adherence rate of 30.9% (95% CI 26.8--35.3%) \[[@CR11]\]. A better understanding of the underlying reasons for suboptimal adherence will enable more informed intervention development. Therefore, the aim of this systematic review was to identify psychological determinants that influence medication adherence in stroke survivors.

Current evidence has considered the role of psychological, demographic, system, biological and other factors when trying to understand medication adherence. Determinants, such as beliefs about medication, presence of other comorbid conditions, age and lack of clinical symptoms have been previously identified as influential in stroke survivors' medication adherence \[[@CR12]--[@CR15]\]. The negative consequences of taking medications, including unpleasant side effects and drug interactions, as well as difficulty accessing the prescribing clinician or pharmacy and issues with prescription costs, could also contribute to non-adherence \[e.g. [@CR11], [@CR16]--[@CR18]\]. Moreover, current interventions have had limited success at effectively improving medication adherence \[e.g. [@CR19]\]. Some determinants of medication adherence, such as age, gender or stroke type \[[@CR11]\], are not easily modified. Therefore, a better understanding of the modifiable determinants of medication adherence is required to facilitate the design of behaviour change interventions. Psychological determinants, defined as determinants of, or relating to, the mind or mental processes, also relating to or affecting a person's emotional state \[[@CR20]\], are one type of potentially modifiable determinant. Considerable research effort has been made to link psychological determinants to the behaviour change techniques (BCTs) likely to change each one \[[@CR21], [@CR22]\]. This could facilitate adherence intervention design. Consequently, the current review focused on identifying the strongest psychological determinants of medication adherence in stroke survivors and considered the quality of the primary studies.

Many theories of the psychological influences on behaviour have been developed (e.g. Theory of Planned Behaviour \[[@CR23]\] and Health Belief Model \[[@CR24], [@CR25]\]). However, such theories of health behaviour have been subject to a number of criticisms, including not always operationalising the constructs clearly, not considering the context in which a behaviour occurs and an over emphasis on rational, deliberative determinants. As there is considerable unexplained variance in adherence, the addition of further predictor variables should enhance the theories (see \[[@CR26]\]). In partial response to the latter two criticisms, the Theoretical Domains Framework (TDF) has been developed \[[@CR27], [@CR28]\].

The TDF was developed via an expert consensus approach. Behaviour change professionals identified constructs from many major behaviour change theories. The identified constructs were clustered using open and closed sort tasks, grouping similar constructs together to form, what the authors termed, a domain. After revisions, 14 key domains were established (Knowledge; Skills; Social/Professional role and identity; Beliefs about capabilities; Optimism; Beliefs about consequences; Reinforcement; Intentions; Goals; Memory, Attention and Decision processes; Environmental context and resources; Social influences; Emotions; and Behavioural regulation \[[@CR28]\]). The TDF provides more comprehensive coverage of influences on behaviour than any single theory of behaviour and was therefore used as a theoretical framework in this review. A further advantage of the TDF is that the domains can be mapped to BCTs that are thought to be most likely to change each type of determinant \[[@CR28], [@CR29]\].

The aim of this systematic review was to identify psychological determinants that influence medication adherence in stroke survivors. The secondary aim was to establish the magnitude of the relationships between the psychological determinants and stroke survivors' medication adherence. To our knowledge, there has not yet been a review, which has mapped identified determinants into the TDF in order to establish a more complete understanding of medication adherence in stroke survivors.

Methods {#Sec2}
=======

This review includes studies focused on people with a clinical diagnosis of stroke (ischaemic or haemorrhagic) and prescribed medications that targeted stroke risk factors for secondary prevention. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed \[[@CR30]\]. The systematic review protocol was prospectively registered on PROSPERO (CRD42015016222).

Search Strategy and Selection Process {#Sec3}
-------------------------------------

The search targeted literature investigating psychological determinants of medication adherence in stroke survivors. A multi-method search was undertaken using combined terms for stroke AND adherence AND psychological determinants and a combination of subject heading and free text searching where applicable (See Supplement [1](#MOESM1){ref-type="media"} for tailored search strategy). Sources included MEDLINE, EMBASE, PsycINFO, CINAHL, Web of Science (inclusive of conference proceedings) and reference lists of included full text articles. The search was limited to English language as this was the only fluent language understood by the review team. The inception date of the search was 1953 because literature regarding "compliance" in healthcare started to appear from the early 1950s \[[@CR31]\]. Eligibility and selection of relevant articles were assessed by first conducting title/abstract review and then by assessing full texts according to predefined inclusion/exclusion criteria. COVIDENCE software was used to manage this process. The selection process, data extraction and quality assessment were performed independently by two reviewers (EC, MF). A third reviewer resolved conflicts and cross-checked data extraction (AJW). Reviewer EC extracted data from all included full texts. Reviewer MF extracted data from a proportion (10%) of the full texts and extracted all subjective and outcome data from the remaining texts (90%). If reviewers required more information, the authors were contacted. Seven of the 19 authors contacted responded. Figure [1](#Fig1){ref-type="fig"} displays the PRISMA diagram of the search and selection process.Fig. 1PRISMA diagram

Criteria for Study Inclusion and Exclusion {#Sec4}
------------------------------------------

Inclusion criteria:Studies with a sample of stroke survivors or mixed transient ischaemic attack (TIA)/stroke survivors who were ≥18 years of age and had been prescribed medication(s) that targeted at least one stroke risk factorPrimary research studies with quantitative research designs measuring at least one psychological determinant and medication adherence

Exclusion criteria:Studies with a sample of stroke survivors \<18 years of ageMixed condition samples where stroke only data could not be obtainedReviews (systematic, narrative or meta-analytic), studies applying retrospective data collection and qualitative study designs

Randomised control trials (RCTs) were not explicitly excluded from the search strategy, but only one RCT identified was relevant to the review research question \[[@CR32]\]. The RCT had been informed and was a sequel to an observational study identifying psychological determinants \[[@CR13]\]. Therefore, for this review, the inclusion of the observational study design was considered most appropriate.

Data Extraction and Analysis {#Sec5}
----------------------------

### Data Extraction {#Sec6}

Data extraction was completed using a proforma developed for this review, in accordance with Cochrane guidance \[[@CR33]\]. The data extracted included: (1) participant clinical and demographic characteristics, (2) study design and methods, (3) adherence measures, (4) identified psychological determinants and (5) statistical information.

### Analysis {#Sec7}

Summary data from each full text were extracted. The analysis within this review focused on the effect sizes of the relationship between medication adherence/persistence and the determinants given. Data collection methods from the included papers were too heterogeneous to allow for a meta-analysis. The determinants were grouped into the relevant TDF domains. To identify which domains were most influential to adherence, assessment of the domains with a higher number of tested determinants with significant associations was carried out. The number of papers and samples that a determinant was tested in was also extracted and used to establish domains with the most influence on medication adherence. Domains were considered more influential when a larger proportion of the tested determinants had significant associations with adherence and where significant associations were found in a higher proportion of the samples in which at least one determinant from the domain was tested.

### Quality Assessment {#Sec8}

Quality assessment was conducted independently by two reviewers (EC, MF) using the 13-item checklist designed by Walburn and colleagues \[[@CR34]\] to appraise studies of attitudes to medicines. The checklist assesses items such as a priori aims, definition/size of population under investigation, sample size calculations and justification that the sample is representative of population. The checklist is not intended to provide a defined cutoff study quality score, below which studies should be excluded from analysis. Instead, using the checklist facilitated qualitative consideration of the impact of study design features on findings.

### Determinant Mapping {#Sec9}

Two coders (EC and SJB), with qualifications in Health Psychology (MSc, PhD and MSc), independently mapped the identified psychological determinants into TDF domains. Domain definitions were taken from the most recent version of the TDF at the time of this review \[[@CR28]\]. One coder (MA), a qualified general practitioner with experience in mental health research, resolved disputes. Determinants were coded into the most suitable domain, or domains if it was agreed that the determinant fitted into more than one, or not coded if none of the domains seemed appropriate. Where possible, the wording of the items used to measure a determinant was checked to ensure domains were coded in line with what was measured, rather than simply the label given to a determinant by the study authors. Cohen's kappa for agreement between the two coders \[[@CR35]\] was *k* = 0.69 (SE = 0.07 \[95% CI = 0.56--0.82\]), indicating substantial agreement.

Results {#Sec10}
=======

A search from inception until November 2015 produced a total of 32,845 articles (duplicates removed). Titles and abstracts were screened, producing 90 full texts to assess. Following assessment of full texts, 12 papers reporting on seven samples met inclusion criteria (Fig. [1](#Fig1){ref-type="fig"}).

Study Characteristics {#Sec11}
---------------------

Detailed study characteristics can be found in Table [1](#Tab1){ref-type="table"}. The 12 papers were derived from seven samples, with another two of the papers posing a potential for overlap. Therefore, results will now be considered by displaying the number of papers (x/12) and number of samples (x/7), relevant to each factor. Most studies (9/12, 5/7) assessed medication adherence. Three of the twelve studies (2/7 samples) assessed medication persistence \[[@CR40], [@CR43], [@CR44]\]. The total sample size was 43,984 (range 25 to 21,077). Research was conducted in four countries (USA, Australia, Sweden and UK) across three continents. Settings for participant recruitment included hospital (5/12, 4/7) \[[@CR39]--[@CR41], [@CR43], [@CR44]\], community (6/12, 2/7) \[[@CR36]--[@CR38], [@CR42], [@CR45], [@CR46]\] and an outpatient setting (1/12, 1/7) \[[@CR13]\]. The reported stroke subtypes included ischaemic (6/12, 5/7) \[[@CR13], [@CR39]--[@CR41], [@CR43], [@CR44]\], haemorrhagic (3/12, 3/7) \[[@CR39], [@CR40], [@CR42]\] and TIA (6/12, 2/7) \[[@CR37], [@CR38], [@CR43]--[@CR46]\], with the majority of papers reporting samples with mixed subtypes (75%). In seven papers (3/7 samples), the stroke subtype was either undefined or only some of the sample's stroke subtypes were defined.Table 1Summary of each included full text articleAuthor/countryDesignParticipantsNumberMedication adherence measurePsychological determinantsPsychological determinant measureKey findings \[95% CI\]*P* values% of max quality score^a^Sample 1Bushnell (2010) / USA \[[@CR43]\]ProspectiveIschaemic stroke (1712) and TIA (465)2177Comparison- discharge vs. current medications (measured by modified MMAQ)Understanding how to refill medicationsUnclear from paperOR 1.64 \[1.04--2.58\]*P* = 0.0361.5Understanding why medications are being takenUnclear from paperOR 1.81 \[1.19--2.76\]*P* = 0.006EQ-5D scoreEuroQoL-5DOR 2.33 \[1.24--4.38\]*P* = 0.009Bushnell (2011) / USA \[[@CR44]\]ProspectiveIschaemic stroke and TIA2092Comparison- discharge vs. current medications (measured by modified MMQ)Receiving medication instructionsThe Primary Care Assessment SurveyOR 1.43 \[1.13--1.81\]*P* \< 0.00361.5Understanding medication side effectsUnclear from paperOR 1.29 \[1.02--1.63\]*P* = 0.032Understanding why medications are being takenUnclear from paperOR 1.49 \[1.03--2.17\]*P* = 0.036Sample 2Edmondson (2013)/ USA \[[@CR45]\]Cross-sectionalTIA and undefined stroke5358 item MMAQPTSD symptomsPCL-SOR 1.02 \[1.00--1.05\]0.1 \> *p* \> 0.05^c^90.9Specific concernsBMQ (specific)OR 1.17 \[1.10--1.25\]*p* \< 0.05^c^Depressive symptomsPHQ-8OR 1.02 \[0.97--1.08\]*p* \> 0.05^c^Kronish (2012)/ USA \[[@CR36]\]Cross-sectionalUndefined stroke5358 item MMAQLikely PTSDPCL-SOR 2.69 \[1.71--4.23\]*P* \< 0.05^c^90.9Possible PTSDPCL-SOR 1.86 \[1.27--2.74\]*p* \< 0.05^c^Depressive symptomsPHQ-8OR 1.12 \[0.88--1.42\]*p* \> 0.05^c^Kronish (2013) /USA \[[@CR46]\]Cross-sectionalTIA and undefined stroke6008 item MMAQHigh concerns about medicationsModified BMQ Specific Concerns (X4 items)OR 5.09 \[2.81--9.24\]*p* \< 0.00190.9Low perceived need of medicationsModified BMQ Specific NecessityOR 1.23 \[0.79--1.91\]*P* = 0.36Low knowledge of stroke risk factorsNV-Qx1 State 3 most important things would recommend to others to lower stroke riskOR 1.22 \[0.76--1.96\]*P* = 0.42Low trust in personal doctorAdapted Trust in Doctors Scale (×3 items)OR 1.30 \[0.84--2.01\]*P* = 0.23Perceive discrimination due to race, ethnicity, education, or incomeNV-5 point Likert scaleOR 1.79 \[1.14--2.81\]*P* = 0.01Phillips (2014) / USA \[[@CR37]\]Cross-sectionalTIA (284) and undefined stroke (316)6008 item MMAQNecessity beliefsAdapted BMQ Specific*β* = 0.25 \[0.07--0.42\]*P* \< 0.0172.7ConcernsAdapted BMQ Specific*β* = −0.81 \[−0.96 to −0.66\]*P* \< 0.001Phillips (2015) / USA \[[@CR38]\]Cross-sectionalTIA (284) and undefined stroke (316)6008 item MMAQAffective illness itemsNV-Q ×1 Level of worry about future stroke*r* = −.27 *p* = 0.001\
*β* −0.14, *R* ^2^ 0.02 (F (1, 564) = 12.33)*P* \< 0.00172.7Cognitive illness itemsNV-Q ×2 How well blood pressure and cholesterol is controlled*r* = 0.29 *p* = 0.001\
*β* 0.18, *R* ^2^ 0.03 (F(1, 564) = 22.16)*P* \< 0.001Affective treatment itemsBMQ Specific Concerns (×3 items)*r* = −0.40 *p* = 0.001\
*β* −0.31, *R* ^2^ 0.08 (F(1, 564) = 56.71)*P* \< 0.001Cognitive treatment itemsBMQ-specific necessity (×3 items) + NV-"'How much do you think medicines can help prevent strokes?"*r* = 0.12 *p* = 0.01\
*β* 0.13, *R* ^2^ 0.02 (F(1, 564) = 11.62)*P* \< 0.01Sample 3Coetzee (2008) /Australia \[[@CR39]\]ProspectiveIschaemic (14) and haemorrhagic (11) stroke25Q1 and 2 on TAS Pill Counts(Partner) Emotional dyscontrolEFQ*r* = −0.66*P* \< 0.0184.6Language skillsEFQ*r* = −0.44*P* \< 0.001MemoryEFQ*r* = −0.54*P* \< 0.001Planning and organisationEFQ*r* = −0.52*P* \< 0.001AngerESDQ*r* = −0.63*P* \< 0.01Emotional dyscontrolESDQ*r* = −0.76*P* \< 0.001HelplessnessESDQr = −o.64*P* \< 0.01InertiaESDQ*r* = −0.61*P* \< 0.01FatigueESDQ*r* = −0.52*P* \< 0.01IndifferenceESDQ*r* = −0.54*P* \< 0.01EUPHORIAESDQ*r* = −0.51*P* \< 0.01(Partner) Emotional dyscontrolESDQ*r* = −0.51*P* \< 0.001(Partner) InertiaESDQ*r* = −0.51*P* \< 0.01AnxietyHADS*r* = −0.74*P* \< 0.001Specific necessityBMQ Specific*r* = −0.53*P* \< 0.01Care received at homeQuestions in TAS*r* = 0.53*P* \< 0.01Sample 4O'Carroll (2011) /UK \[[@CR13]\]ProspectiveIschaemic stroke180Urine samples MARSSpecific medication concernsBMQ Specific*β* = −0.254*P* \< 0.0176.9MMSE scoreMMSE*β* = 0.000 *NSp* \> 0.05^c^Perceived benefit of medicationNV-Adapted Q.s^d^*β* = 0.273*P* \< 0.001RMBT scoreRBMT*β* = 0.167 *NSp* \> 0.05^c^Risk perception of further strokeNV-Visual analogue 0--100 scale*β* = −0.044 *NSp* \> 0.05^c^Illness perceptions-acute/chronic timelineIPQ*β* = 0.002 *NSp* \> 0.05^c^Illness perceptions- treatment controlIPQ*β* = −0.021 *NSp* \> 0.05^c^Specific necessityBMQ specific*β* = −0.022 *NSp* \> 0.05^c^Desire for medications nowNV-Adapted Q.s^1^*β* = −0.140 *NSp* \> 0.05^c^HADS totalHADS*β* = 0.064 *NSp* \> 0.05^c^Sample 5Glader (2010) /Sweden^b^\[[@CR40]\]ProspectiveIschaemic and undefined stroke21,077Data Linkage- RiksStroke with the Swedish Prescribed Drug RegisterSupport of next of kinItems from the RiksStroke RegisterAH: OR 1.13 \[1.02--1.25\]\
S: *NS*\
AP: *NS*\
W: OR 0.98 \[0.76--1.26\]*p* ≤ 0.001\
*p* \> 0.05^c^\
*p* \> 0.05^c^\
*P* ≤ 0.0569.2Self-perceived general healthItems from the RiksStroke RegisterAH: OR 0.86 \[0.76--0.98\]\
S: OR 0.69 \[0.59--0.80\]\
AP: OR 0.79 \[0.70--0.89\]\
W: *NSP* ≤ 0.02\
*P* ≤ 0.001\
*P* ≤ 0.001\
*p* \> 0.05^c^Low moodItems from the RiksStroke RegisterAH: OR 0.88 \[0.79--0.98\]\
S: OR 1.12 \[0.98--1.28\]\
AP: OR 0.92 \[0.83--1.02\]\
W: *NSp* ≤ 0.001\
*P* \< 0.09\
*P* ≤ 0.04\
*p* \> 0.05^c^Satisfaction with hospital care and supportItems from the RiksStroke RegisterAH: *NS*\
S: *NS*\
AP: *NS*\
W: *NSp* \> 0.05^c^\
*p* \> 0.05^c^\
*p* \> 0.05^c^\
*p* \> 0.05^c^Sample 6Sjölander (2011) /Sweden^b^ \[[@CR41]\]ProspectiveIschaemic stroke (men: 9331; women: 9016)19,347Prescription refillsSelf-reported depressionItems from the RiksStroke RegisterMen: PR 0.96 \[0.88--1.05\]\
Women: PR 1.00 \[0.93--1.08\]*p* \> 0.05^c^\
*p* \> 0.05^c^69.2Self-reported bad general healthItems from the RiksStroke RegisterMen: PR 0.99 \[0.90--1.09\]\
Women: PR 0.97 \[0.89--1.06\]*p* \> 0.05^c^\
*p* \> 0.05^c^Dissatisfied with careItems from the RiksStroke RegisterMen: PR 0.92 \[0.74--1.14\]\
Women: PR 0.93 \[0.75--1.16\]*p* \> 0.05^c^\
*p* \> 0.05^c^Dissatisfied with supportItems from the RiksStroke RegisterMen: PR 0.99 \[0.89--1.10\]\
Women: PR 0.99 \[0.90--1.10\]*p* \> 0.05^c^\
*p* \> 0.05^c^Sample 7Sjölander (2013) /Sweden \[[@CR42]\]Cross-sectionalHaemorrhagic (40) and undefined stroke (538)578MARSSpecific necessityBMQOR 0.90 \[0.83--0.98\]*P* = 0.07984.6Specific concernsBMQOR 1.12 \[1.05--1.21\]*P* \< 0.001General overuseBMQOR 1.29 \[1.14--1.45\]*P* \< 0.001General harmBMQOR 1.12 \[1.01--1.24\]*P* = 0.038General benefitBMQOR 0.77 \[0.68--0.87\]*P* \< 0.001*NS* not significant, *MMAQ* Morisky Medication Adherence Questionnaire, *MARS* Medication Adherence Report Scale, *TAS* Treatment Assessment Schedule, *BMQ* Beliefs About Medicines Questionnaire, *PCL-S* Modified PTSD Checklist-Specific to stroke/mini stroke, *EQ-5D* EuroQoL-5D, *PHQ-8* 8-item Patient Health Questionnaire Depression Scale, *EFQ* Everyday Functioning Questionnaire, *ESDQ* The Emotional and Social Dysfunction Questionnaire, *HADS* The Hospital Anxiety and Depression Scale, *MMSE* The Mini-Mental State Examination, *RMBT* The Rivermead Behavioural Memory Test, *IPQ* The Illness Perception Questionnaire, *NV* non-validated, *AH* anti-hypertensives, *S* statins, *AP* anti-platelets, *W* warfarin^a^Percentage of Maximum quality score (see supplementary Material [3](#MOESM3){ref-type="media"} for full quality scoring table)^b^Potential overlap of samples as same data source was utilised across different dates^c^Exact *P* values not reported in original paper;^d^Trewby, P. N., Reddy, A. V., Trewby, C. S., Ashton, V. J., Brennan, G., & Inglis, J. (2002). Are preventive drugs preventive enough? A study of patients' expectation of benefit from preventive drugs. Clin Med., 2(6), 527--533

Time periods between measurement of determinants and adherence varied, with 6/12 papers, 2/7 samples using cross-sectional designs \[[@CR36]--[@CR38], [@CR41], [@CR45], [@CR46]\] and follow-up time frames for prospective studies of 5--6 weeks (1/12, 1/7) \[[@CR13]\], 3 months (2/12, 2/7) \[[@CR42], [@CR43]\], 12 months (2/12, 2/7) \[[@CR39], [@CR44]\] and 24 months (1/12, 1/7) \[[@CR40]\]. A range of questionnaire items (validated and non-validated) was used to measure psychological determinants. Some papers did not clearly describe how determinants were measured.

Measurement of Adherence {#Sec12}
------------------------

A variety of methods were used to measure medication adherence (Supplement [2](#MOESM2){ref-type="media"}). These included the use of self-report measures such as the Medication Adherence Report Scale (MARS) and more objective methods such as conducting pill counts and monitoring prescription refills. In total, seven different methods were applied (3 subjective, 4 objective), either alone or in conjunction with another. Six articles (50%, 5/7 samples) named the specific medications being assessed for adherence. Of these, five considered antiplatelet, anti-hypertensive, cholesterol-lowering and anti-coagulant medications \[[@CR39]--[@CR41], [@CR43], [@CR44]\] and one assessed adherence to antiplatelet, anti-hypertensive and cholesterol-lowering medications \[[@CR13]\].

Quality Assessment {#Sec13}
------------------

Study quality was varied (Supplement [3](#MOESM3){ref-type="media"}). Checklist scores ranged from 8 to 10 (mean = 9.3) out of a possible 13. All included studies reported explicit a priori aims, a sample definition and size, inclusion/exclusion criteria, a response/dropout rate where applicable and whether the research was independent of routine practice. However, only two studies gave a sample size calculation \[[@CR13], [@CR42]\]. In addition, although seven studies stated the response/dropout rate \[[@CR13], [@CR39]--[@CR44]\], which ranged from 56 to 96%, only two provided justification for these rates \[[@CR13], [@CR39]\]. There was no clear justification of sample representativeness in four studies \[[@CR13], [@CR39], [@CR43], [@CR44]\]. In addition, the majority of included studies had designed questionnaires or interview schedules purposely for the research derived from validated and non-validated measures. Three studies did not make the original questionnaire available or provide sufficient information on how all determinants were measured \[[@CR13], [@CR43], [@CR44]\], and four studies did not justify the reliability/validity of the measures used \[[@CR40], [@CR41], [@CR43], [@CR44]\].

Determinant Mapping {#Sec14}
-------------------

There were 48 distinct determinants measured across the 12 papers, reporting on seven samples. The most common determinants (6/12 papers, 4/7 samples) were variations of *concerns about medications* and *beliefs about necessity of medications.* Five of 12 articles (4/7 samples) also assessed *depression* as a determinant of medication adherence. Over half the tested determinants were only measured in one study. Table [2](#Tab2){ref-type="table"} displays the identified determinants from the review mapped into TDF domains. Determinants tested in the papers could be mapped into 8/14 domains. There were no tested determinants that mapped into 'Social/Professional role and identity', 'Optimism', 'Reinforcement', 'Goals', 'Environmental context and resources' and 'Behavioural regulation'. One tested determinant, *quality of life* (as measured by increments of 10% in EuroQoL-5D score) could not be mapped into the TDF, as no definition seemed appropriate. Only four determinants (*patient reported* and *partner reported inertia, patient helplessness* and *affective illness items*) were considered to fit within two separate TDF domains (see Table [2](#Tab2){ref-type="table"} for determinant mapping). All other determinants sat discretely within one domain. A total of 33 distinct determinants, corresponding to seven TDF domains, significantly influenced adherence/persistence behaviour (Table [3](#Tab3){ref-type="table"}). Each domain will now be discussed in turn (for numerical details of observed associations and *p* values, see Table [1](#Tab1){ref-type="table"}).Table 2Determinants mapped into the theoretical domains frameworkDomainDescription^a^DeterminantKnowledge*An awareness of the existence of something*Receiving medication instructionsUnderstanding why medications are being takenUnderstanding medication side effectsLow knowledge of stroke risk factorsUnderstanding how to refill medsSelf-perceived general healthSelf-reported bad general healthSkills*An ability or proficiency acquired through practice*Planning and organisationLanguage skillsSocial/Professional role and identity*A coherent set of behaviours and displayed personal qualities of an individual in a social or work setting*Beliefs about capabilities*Acceptance of the truth, reality, or validity about an ability, talent, or facility that a person can put to constructive use*Cognitive illness itemsHelplessnessOptimism*The confidence that things will happen for the best or that desired goals will be attained*Beliefs about consequences*Acceptance of the truth, reality, or validity about outcomes of a behaviour in a given situation*Concerns about medicationsAffective illness itemsBeliefs about necessityPerceived benefit of medicationCognitive treatment itemsAffective treatment itemsRisk perception of risk of further strokeBeliefs about benefitBeliefs about overuseBeliefs about harmIllness perceptions-acute/chronic timelineIllness perceptions-treatment controlReinforcement*Increasing the probability of a response by arranging a dependent relationship, or contingency, between the response and a given stimulus*Intentions*A conscious decision to perform a behaviour or a resolve to act in a certain way*Desire for medication nowGoals*Mental representations of outcomes or end states that an individual wants to achieve*Memory, Attention and Decision processes*The ability to retain information, focus selectively on aspects of the environment and choose between two or more alternatives*MMSE scoreRMBT scorePatient memoryEnvironmental context and resources*Any circumstance of a person's situation or environment that discourages or encourages the development of skills and abilities, independence, social competence, and adaptive behaviour*Social influences*Those interpersonal processes that can cause individuals to change their thoughts, feelings, or behaviours*Support of next of kinLow trust in personal doctorPerceived discrimination on account of race, ethnicity, education or incomeDissatisfied with careDissatisfied with supportSatisfaction with hospital care/supportCare received at homeInertiaInertia (rated by partner)Emotions*A complex reaction pattern, involving experiential, behavioural, and physiological elements, by which the individual attempts to deal with a personally significant matter or event*Emotional dyscontrol (rated by partner)Emotional dyscontrolAngerPTSD symptoms(Self-reported) Depression/depressive symptomsLow moodFatigueIndifferenceEuphoriaInertiaInertia (rated by partner)HADS totalAnxietyHelplessnessAffective Illness ItemsBehavioural regulation*Anything aimed at managing or changing objectively observed or measured actionsPTSD* post-traumatic stress disorder, *HADS* The Hospital Anxiety and Depression Scale, *MMSE* The Mini-Mental State Examination, *RMBT* The Rivermead Behavioural Memory Test^a^Definitions as stated in Cane et al. 2012 who utilised the definitions from the American Psychological Associations' Dictionary of Psychology Table 3Table showing the number of significant determinants (and their negative or positive influence on adherence) within each domainDomainTotal no. of determinants tested across all papersNo. of determinants significantly associated with better adherenceNo. of determinants significantly associated with worse adherenceNo. (%) of determinants tested not significantly related to adherenceNo. of the 12 papers reporting a test of at least one determinant from this domainNo. of the 7 samples in which at least one determinant from this domain was testedNo. (%) of samples in which determinants were tested and at least one had a significant association with adherenceKnowledge7412 (29%)543 (75%)Skills2020 (0%)111 (100%)Beliefs about capabilities2110 (0%)222 (100%)Beliefs about consequences12453 (25%)744 (100%)Intentions1001 (100%)110 (0%)Memory, attention and decision processes3012 (67%)221 (50%)Social influences9234 (44%)443 (75%)Emotions150132 (13%)743 (75%)

### 'Knowledge' {#Sec15}

Seven distinct determinants mapped into this domain. Two determinants did not have a significant effect on adherence (*self-reported bad general health* and *low knowledge of stroke risk factors).* Five significantly influenced medication adherence/persistence. Generally, greater knowledge was associated with better adherence/persistence. Four significant determinants (*receiving medication instructions, understanding how to refill medications, understanding why medications are being taken* and *understanding medication side effects*) were all related to adherence in this manner. *Self-perceived general health* also had a significant effect on adherence, with poorer *self-perceived general health* associated with poorer medication persistence.

### 'Skills' {#Sec16}

Two distinct determinants tested (*patient language skills* (reported by a partner) and *patient planning and organisation skills*) mapped to this domain. Both determinants had a significant effect on adherence, with poorer skills associated with worse adherence.

### 'Beliefs about Capabilities' {#Sec17}

Two distinct determinants were tested, both significantly influencing medication adherence. *Patient helplessness* had a negative impact on adherence. Rating oneself as more helpless was related to poorer adherence. *Cognitive illness items*, assessing patients' perceived control over stroke risk factors, had a positive impact, with positive responses indicating higher perceived risk factor control related to better self-reported adherence.

### 'Beliefs about Consequences' {#Sec18}

Twelve distinct determinants were mapped to this domain. Three tested determinants were not found to have a significant effect on medication adherence (*illness perceptions* relating to acute/chronic timelines of a condition, *illness perceptions* referring to treatment control and *perceived risk of further stroke*). Four determinants had a significant positive influence on medication adherence. Greater *perceived necessity of medications* was related to increased adherence (in 2/5 papers). Greater *perceived benefit of medications* (measured in two ways) was related to increased adherence. Higher scores on *cognitive treatment items* (derived from items from the specific necessity subscale of the Beliefs about Medications Questionnaire (BMQ) plus a question regarding how much patients thought their medications could prevent stroke) were related to better self-reported adherence.

Five determinants significantly negatively influenced adherence. When patients had greater *concerns about medications*, *beliefs about medication overuse* and *beliefs about harm from medication* adherence was worse. In addition, worse adherence was related to *affective treatment items*, concerning worries about medications and *affective illness items* concerning worries about stroke.

### 'Intentions' {#Sec19}

One determinant (*desire for medications now*) was tested, but not found to have a significant effect on adherence.

### 'Memory, Attention and Decision Processes' {#Sec20}

Three distinct determinants were tested of which two were not significant (*Mini Mental State Exam* (MMSE) *score* and *Rivermead Memory Behavioural Test* (RMBT) *score*). In contrast, *Patient memory* (measured by the Everyday Functioning Questionnaire (EFQ)) significantly influenced medication adherence. Poorer reported memory or memory deficits were related to poorer adherence.

### 'Social Influences' {#Sec21}

Nine distinct determinants were tested and mapped into this domain. Four (*low trust in personal doctor*, *dissatisfaction with care*, *dissatisfaction with support* and *satisfaction with hospital care/support*) did not have a significant effect on medication adherence/persistence. Two determinants had a significant positive influence on medication adherence/persistence. *Increased support from the next of kin* was related to better persistence with anti-hypertensive and warfarin medications. Moreover, higher levels of *care received at home* were associated with better adherence. In contrast, three determinants negatively influenced adherence. Greater *perceived discrimination due to race, ethnicity, education or income* increased odds of non-adherence. In addition, both *patient-rated* and *partner-rated inertia* influenced adherence negatively. Increasing levels of inertia appeared to relate to increased non-adherence.

### 'Emotions' {#Sec22}

Fifteen distinct determinants were tested. Two determinants ((*self-reported) depression/depressive symptoms* and Hospital Anxiety and Depression Scale (HADS) *total score*) were not significantly associated with medication adherence. Thirteen determinants had a significant negative influence on adherence/persistence. Adherence/persistence was poorer when patients had greater *patient-reported* or *partner-rated emotional dyscontrol* (measured via two different measures); *post-traumatic stress disorder* (PTSD) *symptoms*; more *anger*; greater *patient-reported* or *partner-rated inertia*; more *fatigue*, *euphoria*, *indifference*, *anxiety*, *low mood*; and higher perceived *helplessness* or scores on *affective illness items* (concerning worries about stroke).

Discussion {#Sec23}
==========

The purpose of this review was to identify psychological determinants that influence medication adherence in stroke survivors. Forty-eight distinct determinants were assessed in 12 articles representing seven samples. The identified determinants were mapped into TDF domains, in order to develop a theoretical understanding of how these determinants influence medication adherence and to inform future work. Based on this review, the 'Emotions' (at least one significant determinant in 3/4 samples in which they were tested, 86% of tested associations statistically significant), 'Knowledge' (at least one significant determinant in 3/4 samples in which they were tested, 79% of tested associations statistically significant) and 'Beliefs about consequences' domains (at least one significant determinant in 4/4 samples in which they were tested, 75% of associations statistically significant) appear to have the strongest influence on medication adherence. The TDF has enabled a holistic approach to understanding medication adherence that will be important in future intervention development.

Within the Emotions domain, emotional distress such as '*anxiety*', '*PTSD*' and '*emotional dyscontrol*' was found to have an influence on medication adherence. Similar findings have emerged in recent literature, corroborating this finding. For example, Gentil and colleagues (2012) assessed anti-hypertensive medication adherence in community-living older adults, finding that adherence was lower when participants had an anxiety or depressive disorder \[[@CR47]\]. In addition, a large American study (*n* = 1342) found a significant association between the presence of mental health conditions (anxiety/depression) and difficulty taking anti-hypertensive medications \[[@CR17]\].

Within the 'Knowledge' domain, *understanding why medications were being taken* and *understanding medication side effects* were found to have influence on medication adherence. Previous literature has found to be similar. A prospective cohort study interviewing 130 stroke survivors and 85 caregivers found large gaps in stroke survivor and caregiver knowledge. For example, 52% of patients were unable to name stroke risk factors. This sample also demonstrated suboptimal health behaviours, with 28% of the patients reporting non-adherence \[[@CR48]\]. More recently, a qualitative study identifying barriers to medication adherence with stroke survivors, caregivers and general practitioners in the East of England found similar results \[[@CR49]\]. Knowledge of stroke and medication was identified as a patient-level barrier to adherence of secondary prevention medication \[[@CR49]\].

Within the 'Beliefs about consequences' domain, both *concerns about medication* and *beliefs about the necessity of medication* were the most common determinants with influence. This is commensurate with previous research. In a meta-analytic review assessing the influence of necessity beliefs and concerns on adherence in patients with long-term conditions, higher adherence was related to increased beliefs about necessity of treatment. Likewise, poorer adherence was associated with increased concerns about treatment \[[@CR50]\]. Moreover, recent research suggests interventions targeting perceived necessity and concerns about medications increase stroke survivors' medication adherence \[[@CR32], [@CR51]\]. Therefore, those beliefs appear to play a causal role in adherence.

Quality of Included Studies {#Sec24}
---------------------------

All 12 included studies gave clear descriptions of sample demographics, inclusion/exclusion criteria and sample size. Moreover, although there was disparity in the range of sample sizes (25--21,077), there was a pooled sample of 43,984 stroke survivors. These samples were derived from four countries across three continents. In light of this, it can be assumed, with a certain level of confidence, that the reviews findings are generalizable to stroke survivors from developed, western cultures.

There were no defined cutoffs for quality assessment scores. Nevertheless, assessment of the individual items, for each paper, was important to identify gaps in research quality. Only two papers reported a sample size calculation. This is problematic when meta-analysis is not possible, as the finding that some determinants tested did not significantly influence adherence may be due to small sample sizes and underpowered studies, rather than genuine lack of relationships. Moreover, three studies did not make the original questionnaire available or provide sufficient information on measurement of determinants \[[@CR13], [@CR43], [@CR44]\]. As several studies used tailor-made questionnaires, including a mix of non-validated and validated scales, it would be helpful to future systematic reviewers to make the full questionnaires available.

Additionally, there were only seven discrete samples of participants across the 12 papers. Two papers \[[@CR43], [@CR44]\] reported on the same sample, followed up at different time points. Five papers \[[@CR36]--[@CR38], [@CR45], [@CR46]\] used the same sample of trial participants' baseline data, with each paper testing different combinations of determinants that might influence medication adherence. We have therefore presented not only the number of determinants tested that were found to be significant but also the proportion of samples in which a type of determinant was both tested and found to be a significant predictor. Given the relatively small number of independent samples included in this review, and the partial coverage of the TDF domains in the included studies, there remains a need for further, well-designed studies of the predictors of medication adherence in stroke survivors.

The secondary aim of this review, to establish the magnitude of the relationships between determinants and behaviour, could not be achieved, as study design choices were too heterogeneous to permit meta-analysis. Measurement of medication adherence was inconsistent across included papers, with different self-report or objective measures chosen, assessing adherence at a number of different time points. This has been identified as an issue in previous research attempting to synthesise data regarding medication adherence \[e.g. [@CR19]\]. All methods of adherence measurement have limitations. Electronic, objective monitoring may be the best currently available option, but nevertheless can be reactive and is costly. Prescription data provides information about medication possession, but not whether medication was taken, while self-report measures are subject to recall and social desirability biases. The majority of studies in the review used self-report measures. Future research might usefully further explore psychological and other predictors of adherence to stroke secondary preventive medication using objective adherence measurement.

It could be suggested that the varying methods of medication adherence measurement add strength to the findings in this review. For example, the determinant *concerns about medications* was measured across five studies (3/7 samples) \[[@CR13], [@CR37], [@CR42], [@CR45], [@CR46]\], with a significant relationship identified between this determinant and medication adherence. Across the five studies, medication adherence was measured by three different self-report and one pill count method. Irrespective of the measurement method, a significant relationship was found, thus strengthening the conclusion that there is a relationship between determinant and behaviour.

Limitations {#Sec25}
-----------

The number of papers that met final inclusion criteria was small. Authors were contacted (*N* = 19) to request more information or manuscripts relating to data that had previously been presented at conferences or where no full text access could be found, but only seven responded. Other systematic reviewers have reported a similar issue \[[@CR52]\].

In spite of the rigorous method applied to determinant mapping, there is still an element of subjectivity in the process. The task relies on interpretation of TDF domain definitions and descriptions of scales provided in the primary studies.

No determinants were mapped into six TDF domains. However, other research has highlighted the importance of some of these domains in sustained behaviour change. For example, Nicholson and colleagues (2014) identified the importance of 'Environmental context and resources' with the engagement of physical activity in stroke survivors \[[@CR53]\]. The limited breadth of domains tested through this review may represent a 'file drawer' problem or limitations in the study designs. This may also be in part due to the inclusion of only psychological determinants, which could be less likely to map into some TDF domains. In particular, the search strategy would have retrieved studies that assessed the association of stroke survivors' perceptions of their environmental context and resources with adherence, but not studies simply testing whether the presence or absence of different environmental and contextual features influenced adherence. Factors such as prescription costs and health insurance coverage also need to be considered. However, non-adherence remains an issue even in healthcare systems providing universal healthcare coverage and prescriptions free of charge (e.g. 13). Therefore, understanding psychological determinants of adherence remains an important issue to inform intervention design. Despite efforts in the search strategy to access a variety of literature, the 12 selected papers were all identified from the peer-reviewed literature; none were found in the 'grey' literature, which could result in publication bias. Future work should aim to measure a broader range of psychological determinants that influence medication adherence in stroke survivors to enhance a more holistic understanding of this behaviour.

Conclusions {#Sec26}
===========

The findings from this review have identified psychological determinants, amenable to change, that influence medication adherence in stroke survivors. 'Beliefs about Consequences', 'Knowledge' and 'Emotions' were the most influential domains. As the TDF underpins the Behaviour Change Wheel, a framework for intervention development, future work can systematically identify the intervention functions and BCTs that target the determinants within each domain. In doing so, there is a greater chance that medication adherence will be enhanced as the intervention will be grounded in both a theoretical understanding of the behaviour and will be applying evidence into practice. Future research should strive for clarity and transparency to support pooling of data, most specifically focused on consistency of medication adherence measurement and testing of a broad range of determinants using standardised measures.
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